Immunocore Holdings plc (NASDAQ:IMCR) kneel downs to $44.75 per share that compromise more than 22% in last trading session after the firm revealed initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types.
The preliminary results of IMC-ongoing F106C’s Phase 1 dosage escalation study will be presented today at 4:40 PM CEST/10:40 AM EDT in the Investigational Immunotherapy Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress. The presentation is available in the ‘News & Events’ section of the Company’s website’s Investor Relations section.
Chief Executive Officer of Immunocore, Bahija Jallal stated that the long-term results in severely pre-treated patients demonstrate that their PRAME-targeted bispecific medication, IMC-F106C, can help patients with a variety of cancer types. Based on these positive findings, they have begun expansion arms in a variety of tumor types to further evaluate effectiveness.
Chief of the firm Dr. Omid Hamid said: “ImmTAC therapies are designed to provide potent and target-specific T-cell response, overcoming resistance in immune excluded tumors. Through redirection and activation of non-tumor-specific T cells, as shown in this trial with IMC-F106C, we can influence a diverse range of tumors leading to durable response. This trial shows tolerability and activity in a wide range of tumors, including checkpoint inhibitor pre-treated patients. I look forward to upcoming cohorts in combination with checkpoint inhibitors and chemotherapy.”
Patient recruitment in four expansion arms in cutaneous melanoma, ovarian, non-small cell lung cancer (NSCLC), and endometrial malignancies has begun. The IMC-F106C-101 study is adaptive and includes a Phase 2 expansion option, allowing for roughly 100 patients per tumor type to be treated in the Phase 1 and 2 expansion arms. Dose escalation in other solid tumors is ongoing, and preparations for combination arms with standard-of-care are in the works.
Blake Steve is an accomplished writer, researcher, and technology expert specializing in product research and reviews. With an extensive background in the field, Blake has developed a keen eye for evaluating and analyzing various products across a wide range of industries.
Blake’s passion for technology and gadgets sparked at an early age, and he has since dedicated his career to staying at the forefront of technological advancements. He possesses an in-depth understanding of the latest trends, developments, and innovations in the tech world, enabling him to provide insightful and comprehensive reviews.
Armed with an analytical mindset and exceptional research skills, Blake delves deep into product specifications, features, and user experiences. His ability to break down complex technical details into easily understandable terms allows readers to make informed decisions when it comes to purchasing products.